Kelly Schick C4 Therapeutics, Inc. (CCCC) insider trading activity

Kelly Schick is Chief People Officer of C4 Therapeutics, Inc.. Currently has a direct ownership of 108,885 shares of CCCC, which is worth approximately $327,743. The most recent transaction as insider was on Feb 14, 2025, when has been sold 2,368 shares (Common Stock) at a price of $3.18 per share, resulting in proceeds of $7,530. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 109K

92.76% 3M change

108.39% 12M change

Total Value Held $327,743

Kelly Schick Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 14 2025	SELL Payment of exercise price or tax liability	$7,530 $3.18 p/Share	2,368 Reduced 2.13%	108,885 Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	56,500 Added 33.68%	111,253 Common Stock
Feb 13 2025	SELL Payment of exercise price or tax liability	$5,552 $3.2 p/Share	1,735 Reduced 3.07%	54,753 Common Stock
Nov 07 2024	SELL Payment of exercise price or tax liability	$6,656 $6.04 p/Share	1,102 Reduced 1.91%	56,488 Common Stock
Nov 07 2024	BUY Exercise of conversion of derivative security	-	3,750 Added 6.11%	57,590 Common Stock
Sep 16 2024	SELL Payment of exercise price or tax liability	$4,203 $6.36 p/Share	661 Reduced 1.21%	53,840 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	-	2,250 Added 3.96%	54,501 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	27,300 Added 34.32%	52,251 Common Stock
Feb 13 2024	SELL Payment of exercise price or tax liability	$11,329 $6.53 p/Share	1,735 Reduced 6.5%	24,951 Common Stock
Aug 30 2023	SELL Payment of exercise price or tax liability	$1,936 $2.93 p/Share	661 Reduced 2.42%	26,686 Common Stock
Aug 30 2023	BUY Exercise of conversion of derivative security	-	2,250 Added 7.6%	27,347 Common Stock
Feb 13 2023	BUY Grant, award, or other acquisition	-	20,000 Added 44.35%	25,097 Common Stock
Jan 30 2023	SELL Payment of exercise price or tax liability	$10,121 $7.78 p/Share	1,301 Reduced 20.33%	5,097 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	-	3,750 Added 36.95%	6,398 Common Stock
May 25 2022	BUY Exercise of conversion of derivative security	-	3,750 Added 50.0%	3,750 Common Stock

Also insider at

AMAG

AMAG PHARMACEUTICALS, INC.

Chief Human Resources Officer

Kelly Schick

Chief People Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Value

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

Operation

Value

Type

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC

Account